Zinbryta and Abdominal pain - a phase IV clinical study of FDA data

Summary:

Abdominal pain is reported as a side effect among people who take Zinbryta (daclizumab), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Mavenclad, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Abdominal pain when taking Zinbryta. It is created by eHealthMe based on reports of 2,381 people who have side effects when taking Zinbryta from the FDA, and is updated regularly.

What is Zinbryta?

Zinbryta has active ingredients of daclizumab. eHealthMe is studying from 2,382 Zinbryta users. Check the latest studies of Zinbryta.

What is Abdominal pain?

Abdominal pain is found to be associated with 3,233 drugs and 5,742 conditions by eHealthMe. Check the latest studies of Abdominal pain.

On Jul, 11, 2026

2,381 people reported to have side effects when taking Zinbryta.
Among them, 26 people (1.09%) have Abdominal pain.

Among these 26 people:

How long have people been on Zinbryta when they have Abdominal pain? *

What is the gender of people who have Abdominal pain when taking Zinbryta? *

female: 92 %
male: 8 %

What is the age of people who have Abdominal pain when taking Zinbryta? *

What are other drugs people take besides Zinbryta? *

What are other side effects people have besides Abdominal pain? *

Nausea (feeling of having an urge to vomit): 12 people, 46.15%
Headache (pain in head): 11 people, 42.31%
Pain: 7 people, 26.92%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 23.08%
Diarrhea: 6 people, 23.08%
Dermatitis Allergic (inflammation of the skin due allergic reaction): 6 people, 23.08%
Hair Loss: 6 people, 23.08%
Peripheral Swelling: 5 people, 19.23%
Hypersensitivity: 5 people, 19.23%
Drug Hypersensitivity: 5 people, 19.23%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 16 people, 61.54%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 12 people, 46.15%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 6 people, 23.08%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 6 people, 23.08%
Fatigue (feeling of tiredness): 6 people, 23.08%
Pain: 4 people, 15.38%
Oedema (fluid collection in tissue): 4 people, 15.38%
Depression: 4 people, 15.38%
Thyroid Diseases: 3 people, 11.54%
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Zinbryta and have Abdominal pain?

- Check whether Abdominal pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zinbryta:

Zinbryta (2,382 reports)

Abdominal pain treatments and more:

Abdominal pain (286,410 reports)

Browse all side effects of Zinbryta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Abdominal pain:

Abdominal pain (3,233 drugs)

Browse all the conditions that are associated with Abdominal pain:

Abdominal pain (5,742 conditions)

Related publications that referenced our studies

Bhuvan KC, ALrasheedy AA, Ibrahim MI, "A case report from Nepalese community pharmacy on levofloxacin induced severe abdominal pain", Saudi Pharmaceutical Journal, 2013 Jul .
Bhuvan KC, ALrasheedy AA, Ibrahim MI, "A case report from Nepalese community pharmacy on levofloxacin induced severe abdominal pain", Saudi Pharmaceutical Journal, 2013 Jul .

How the study uses the data?

The study uses data from the FDA. It is based on daclizumab (the active ingredients of Zinbryta) and Zinbryta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.